« Return to News | Clinical Intelligence

FDA approves XEOMINR

Friday, July 22, 2011 10:19 AM

Merz Aesthetics said the FDA has approved XEOMINR (incobotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients.

"XEOMIN is a promising new option for both patients and physicians and we are encouraged by the response rates seen in the phase III clinical trials," said Derek H. Jones, M.D., an investigator for the XEOMIN U.S. study, clinical associate professor of medicine at the University of California Los Angeles, and director of Skin Care and Laser Physicians in Beverly Hills, Calif.

The approval of XEOMIN is based on the results of two U.S. clinical trials involving 16 investigative sites and 547 healthy adult patients. In both studies, XEOMIN significantly improved the appearance of glabellar lines 30 days following the first injection, when compared to placebo. XEOMIN is the only botulinum toxin currently approved in the U.S. that does not require refrigeration prior to reconstitution.

XEOMIN is approved for the temporary improvement in the appearance of glabellar lines in 14 countries in the European Union including Germany, the U.K., France, Italy and Spain, under the brand name BOCOUTURER.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.